Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2011 Feb 1;29(4):355-61.
doi: 10.1200/JCO.2010.30.5979. Epub 2010 Nov 1.

Comorbidity and mortality results from a randomized prostate cancer screening trial

E David Crawford  1 , Robert Grubb 3rd, Amanda Black, Gerald L Andriole Jr, Ming-Hui Chen, Grant Izmirlian, Christine D Berg, Anthony V D'Amico
Affiliations
Randomized Controlled Trial

Comorbidity and mortality results from a randomized prostate cancer screening trial

E David Crawford et al. J Clin Oncol. .

Abstract

Purpose: Estimates of prostate cancer-specific mortality (PCSM) were similar for men randomly assigned to intervention compared with usual care on the Prostate, Lung, Colorectal and Ovarian PC screening study. However, results analyzed by comorbidity strata remain unknown.

Patients and methods: Between 1993 and 2001, of 76,693 men who were randomly assigned to usual care or intervention at 10 US centers, 73,378 (96%) completed a questionnaire that inquired about comorbidity and prostate-specific antigen (PSA) testing before random assignment. Fine and Gray's multivariable analysis was performed to assess whether the randomized screening arm was associated with the risk of PCSM in men with no or minimal versus at least one significant comorbidity, adjusting for age and prerandomization PSA testing.

Results: After 10 years of follow-up, 9,565 deaths occurred, 164 from PC. A significant decrease in the risk of PCSM (22 v 38 deaths; adjusted hazard ratio [AHR], 0.56; 95% CI, 0.33 to 0.95; P = .03) was observed in men with no or minimal comorbidity randomly assigned to intervention versus usual care, and the additional number needed to treat to prevent one PC death at 10 years was five. Among men with at least one significant comorbidity, those randomly assigned to intervention versus usual care did not have a decreased risk of PCSM (62 v 42 deaths; AHR, 1.43; 95% CI, 0.96 to 2.11; P = .08).

Conclusion: Selective use of PSA screening for men in good health appears to reduce the risk of PCSM with minimal overtreatment.

PubMed Disclaimer

Conflict of interest statement

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Figures

Fig 1.
Fig 1.
(A) Unadjusted cumulative incidence estimates of prostate cancer incidence in men with no or minimal comorbidity randomly assigned to usual care or intervention. k-sample P = .04. (B) Unadjusted cumulative incidence estimates of prostate cancer incidence in men with at least one significant comorbidity randomly assigned to usual care or intervention. k-sample P < .001.
Fig 2.
Fig 2.
(A) Unadjusted cumulative incidence estimates of prostate cancer–specific mortality in men with no or minimal comorbidity randomly assigned to usual care or intervention. k-sample P = .03. (B) Unadjusted cumulative incidence estimates of prostate cancer–specific mortality in men with at least one significant comorbidity randomly assigned to usual care or intervention. k-sample P = .07. Bonferroni adjustment for a significant P value was < .05 ÷ 2 or .025.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Andriole GL, Crawford ED, Grubb RL, 3rd, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360:1310–1319. - PMC - PubMed
    1. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European Study. N Engl J Med. 2009;360:1320–1328. - PubMed
    1. D'Amico AV, Chen MH, Roehl KA, et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med. 2004;351:125–135. - PubMed
    1. Roberts WB, Han M. Clinical significance and treatment of biochemical recurrence after definitive therapy for localized prostate cancer. Surg Oncol. 2009;18:268–274. - PMC - PubMed
    1. Freedland SJ, Humphreys EB, Mangold LA, et al. Death in patients with recurrent prostate cancer after radical prostatectomy: Prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol. 2007;25:1765–1771. - PubMed

Publication types

Substances